TG Therapeutics Inc vs Unusual Machines Inc. Common Stock — how do they compare? TG Therapeutics Inc trades at $54.41 (market cap $8.32B), while Unusual Machines Inc. Common Stock trades at $17.15 (market cap $885.73M). The key difference: TG Therapeutics Inc is far larger — about 9.4× Unusual Machines Inc. Common Stock's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Unusual Machines Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Unusual Machines Inc. Common Stock for 0 Days on average.
| TGTX | UMAC | |
|---|---|---|
Market Cap | $8.32B | $885.73M |
Volume | 1,285,303 | 3,688,533 |
Sector | Health | Technology |
52-Week High | $59.06 | $34.06 |
52-Week Low | $26.94 | $7.76 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $8.52B | $572.51M |
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics trades at $54.34, down 1.68% today, with a bullish technical outlook supported by moving averages. The company shows strong profitability with 55.22% net income margin and 100.28% ROE, though recent quarters saw EPS misses. Revenue guidance for 2026 is raised to $950M for BRIUMVI, with institutional buying interest from major banks. A shareholder investigation by Kuehn Law presents legal overhang.
Outlook remains positive given analyst consensus target of $80.50 (48% upside) and buyout speculation. Key risks include ongoing legal scrutiny and reliance on BRIUMVI's market share growth. The stock offers growth potential but requires monitoring of legal developments and competitive pressures in the MS treatment space.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →Unusual Machines Inc. manufactures and sells drone components and complete drones for consumer, enterprise, and defense markets, operating brands including Fat Shark FPV goggles and the Rotor Riot retail platform, with US-based, NDAA-compliant manufacturing.
Read more on UMAC →